Teva Pharmaceutical Industries ROA 2012-2026 | TEVA

Current and historical return on assets (ROA) values for Teva Pharmaceutical Industries (TEVA) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
Unlock Macrotrends Premium
40 years of data
Faster, ad-free pages
Unlimited data exports
Full-width charts
Teva Pharmaceutical Industries ROA - Return on Assets Historical Data
Date TTM Net Income Total Assets Return on Assets
2026-03-31 $1.57B $40.19B 3.89%
2025-12-31 $1.41B $39.79B 3.54%
2025-09-30 $0.71B $39.43B 1.81%
2025-06-30 $-0.16B $39.91B -0.40%
2025-03-31 $-1.29B $40.21B -3.20%
2024-12-31 $-1.64B $41.30B -3.97%
2024-09-30 $-0.96B $42.34B -2.26%
2024-06-30 $-0.45B $42.42B -1.07%
2024-03-31 $-0.48B $42.86B -1.12%
2023-12-31 $-0.56B $43.03B -1.30%
2023-09-30 $-2.34B $43.16B -5.42%
2023-06-30 $-2.35B $43.70B -5.38%
2023-03-31 $-1.71B $44.41B -3.85%
2022-12-31 $-2.45B $45.31B -5.40%
2022-09-30 $-1.29B $46.23B -2.79%
2022-06-30 $-1.05B $47.13B -2.24%
2022-03-31 $-0.62B $47.94B -1.28%
2021-12-31 $0.42B $48.43B 0.86%
2021-09-30 $0.73B $49.17B 1.48%
2021-06-30 $-3.92B $49.64B -7.89%
2021-03-31 $-3.98B $51.09B -7.79%
2020-12-31 $-3.99B $52.68B -7.57%
2020-09-30 $-4.03B $54.38B -7.41%
2020-06-30 $0.00B $56.26B 0.01%
2020-03-31 $-0.83B $57.37B -1.44%
2019-12-31 $-1.00B $58.50B -1.71%
2019-09-30 $-4.05B $59.30B -6.83%
2019-06-30 $-4.01B $61.26B -6.54%
2019-03-31 $-3.56B $63.16B -5.64%
2018-12-31 $-2.40B $65.49B -3.66%
2018-09-30 $-11.06B $67.97B -16.27%
2018-06-30 $-10.26B $73.23B -14.01%
2018-03-31 $-16.05B $78.06B -20.56%
2017-12-31 $-16.53B $83.58B -19.77%
2017-09-30 $-5.96B $89.19B -6.69%
2017-06-30 $-6.15B $92.36B -6.65%
2017-03-31 $0.08B $85.25B 0.09%
2016-12-31 $0.07B $76.21B 0.09%
2016-09-30 $1.59B $66.51B 2.39%
2016-06-30 $1.35B $53.98B 2.49%
2016-03-31 $1.70B $52.09B 3.26%
2015-12-31 $1.57B $50.05B 3.14%
2015-09-30 $1.78B $48.09B 3.69%
2015-06-30 $2.55B $47.59B 5.35%
2015-03-31 $2.76B $46.68B 5.91%
2014-12-31 $3.06B $46.66B 6.55%
2014-09-30 $2.75B $46.94B 5.85%
2014-06-30 $2.58B $47.25B 5.47%
2014-03-31 $1.38B $47.44B 2.92%
2013-12-31 $1.27B $47.73B 2.66%
2013-09-30 $1.21B $48.51B 2.49%
2013-06-30 $0.42B $48.94B 0.86%
2013-03-31 $1.73B $49.29B 3.52%
2012-12-31 $1.96B $49.89B 3.94%
2012-09-30 $2.15B $49.77B 4.32%
2012-06-30 $3.14B $47.69B 6.59%
2012-03-31 $2.86B $45.51B 6.28%
2011-12-31 $2.76B $42.71B 6.46%
2011-09-30 $3.02B $39.71B 7.62%
2011-06-30 $3.16B $39.15B 8.07%
2011-03-31 $3.38B $37.91B 8.91%
2010-12-31 $3.33B $36.61B 9.10%
2010-09-30 $2.94B $35.52B 8.27%
2010-06-30 $2.54B $34.09B 7.45%
2010-03-31 $2.26B $33.35B 6.78%
2009-12-31 $2.00B $32.90B 6.08%
2009-09-30 $0.93B $32.67B 2.86%
2009-06-30 $0.92B $30.59B 3.01%
2009-03-31 $0.94B $28.78B 3.26%
2008-12-31 $0.64B $26.88B 2.36%
2008-09-30 $1.89B $24.51B 7.72%
2008-06-30 $1.78B $23.89B 7.46%
2008-03-31 $1.76B $23.07B 7.62%
2007-12-31 $1.95B $22.17B 8.80%
2007-09-30 $1.84B $21.44B 8.59%
2007-06-30 $1.92B $20.81B 9.24%
2007-03-31 $1.90B $20.22B 9.38%
2006-12-31 $0.55B $19.55B 2.79%
2006-09-30 $0.39B $17.03B 2.29%
2006-06-30 $0.05B $14.45B 0.35%
2006-03-31 $-0.20B $11.96B -1.64%
2005-12-31 $1.07B $9.75B 10.99%
2005-09-30 $1.05B $9.56B 10.94%
2005-06-30 $1.03B $9.42B 10.94%
2005-03-31 $1.02B $9.26B 11.02%
2004-12-31 $0.33B $9.02B 3.69%
2004-09-30 $0.24B $8.09B 2.97%
2004-06-30 $0.15B $7.17B 2.02%
2004-03-31 $0.13B $6.28B 1.99%
2003-12-31 $0.69B $5.36B 12.89%
2003-09-30 $0.64B $5.04B 12.74%
2003-06-30 $0.58B $4.66B 12.48%
2003-03-31 $0.46B $4.30B 10.78%
2002-12-31 $0.41B $3.96B 10.39%
2002-09-30 $0.35B $3.66B 9.66%
2002-06-30 $0.34B $3.54B 9.52%
2002-03-31 $0.31B $3.30B 9.35%
2001-12-31 $0.28B $3.13B 8.90%
2001-09-30 $0.26B $2.97B 8.61%
2001-06-30 $0.22B $2.13B 10.54%
2001-03-31 $0.21B $1.41B 14.51%
2000-12-31 $0.19B $0.71B 26.33%
2000-09-30 $0.17B $0.43B 39.67%
2000-06-30 $0.16B $0.43B 37.11%
2000-03-31 $0.15B $0.43B 33.84%
1999-12-31 $0.14B $0.43B 31.51%
1999-09-30 $0.10B $0.36B 26.74%
1999-06-30 $0.09B $0.36B 23.68%
1999-03-31 $0.07B $0.36B 19.78%
1998-12-31 $0.07B $0.36B 18.94%
1998-09-30 $0.07B $0.30B 22.56%
1998-06-30 $0.08B $0.30B 26.26%
1998-03-31 $0.10B $0.30B 31.99%
1997-12-31 $0.10B $0.30B 34.01%
1997-09-30 $0.13B $0.31B 42.22%
1997-06-30 $0.12B $0.31B 38.36%
1997-03-31 $0.09B $0.31B 27.72%
1996-12-31 $0.08B $0.31B 24.82%
1996-09-30 $0.07B $0.22B 30.77%
1996-06-30 $0.07B $0.22B 29.85%
1996-03-31 $0.08B $0.22B 38.12%
1995-12-31 $0.08B $0.22B 36.74%
1995-09-30 $0.08B $0.17B 46.75%
1995-06-30 $0.07B $0.17B 43.79%
1995-03-31 $0.07B $0.30B 24.48%
1994-12-31 $0.07B $0.45B 15.69%
1994-09-30 $0.07B $0.42B 16.03%
1994-06-30 $0.07B $0.56B 11.63%
1994-03-31 $0.06B $0.56B 10.92%
1993-12-31 $0.06B $0.53B 10.85%
1993-09-30 $0.05B $0.49B 10.34%
1993-06-30 $0.05B $0.62B 8.74%
1993-03-31 $0.06B $0.74B 7.57%
1992-12-31 $0.05B $0.85B 5.99%
1992-06-30 $0.04B $0.76B 5.14%
1991-03-31 $0.02B $0.49B 4.86%
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $35.437B $17.258B
Teva Pharmaceutical Industries Limited is a global pharmaceutical company that develops, manufactures, and markets both branded and generic drugs, as well as active pharmaceutical ingredients in North America, Europe, Latin America, India, and Israel. Teva's generic product portfolio includes tablets, capsules, liquids, ointments, creams, liquids, injectables, and inhalants. The company's branded products include Copaxone, Austedo, respiratory products like ProAir and Qvar and Ajovy. Teva operates through three segments, North America, Europe and International Markets, each of which includes generics, specialty and over-the-counter products. Teva acquired Allergan's generics business Actavis Generics. The company also acquired Allergan's Anda Inc. Teva acquired Auspex Pharmaceuticals and Barr. Teva has strengthened its position in Europe through its acquisition of Germany's second largest generics producer, ratiopharm.
Stock Name Country Market Cap PE Ratio
BridgeBio Pharma (BBIO) United States $14.460B 0.00
Dr Reddy's Laboratories (RDY) India $11.109B 17.29
Aspen Pharmacare (APNHY) South Africa $3.708B 0.00
Supernus Pharmaceuticals (SUPN) United States $2.918B 22.33
Bausch Health Cos (BHC) Canada $2.086B 1.50
Taysha Gene Therapies (TSHA) United States $1.290B 0.00
Amphastar Pharmaceuticals (AMPH) United States $0.924B 7.28
Personalis (PSNL) United States $0.630B 0.00
Assembly Biosciences (ASMB) United States $0.451B 0.00
Sol-Gel Technologies (SLGL) Israel $0.210B 0.00
Metagenomi Therapeutics (MGX) United States $0.052B 0.00
Evoke Pharma (EVOK) United States $0.019B 0.00
Teligent (TLGT) United States $0.000B 0.00